Table 1 Baseline characteristics
Control group N = 25 | Experimental group N = 25 | All patients N = 50 | ||
|---|---|---|---|---|
Age (years) | 57 [46–70] | 56 [39–67] | 57 [44–69] | 0.47 |
Male | 13 (52) | 15 (60) | 28 (56) | 0.58 |
Knaus score | 0.21 | |||
A | 20 (80) | 16 (64) | 36 (72) | |
B | 4 (16) | 7 (28) | 11 (22) | |
C | 1 (4) | 1 (4) | 2 (4) | |
D | 0 (0) | 1 (4) | 1 (2) | |
SAPSII | 21 [17–33] | 30 [17–34] | 26 [17–34] | 0.58 |
MRC sumscore (/50) | 38 [30–42.75] | 28 [22.5–37] | 33 [25–40] | 0.043 |
Facial palsy | 5 (22) | 9 (39) | 14 (30) | 0.21 |
Swallowing impairment | 13 (52) | 12 (48) | 25 (50) | 1.00 |
FVC (ml) | 1460 [1105–2335] | 1726 [1206–1888] | 1600 [1184–2075] | 0.84 |
FVC (%pred) | 51 [41.25–58] | 47 [40–54] | 49 [40–56] | 0.22 |
MIP (cmH20) | 30 [20–43] | 45 [26–50] | 40 [21–50] | 0.21 |
MEP (cmH20) | 32.5 [28–43·25] | 50 [35–57.5] | 40 [30–52.5] | 0.12 |
FiO2 (%) | 21 [21–60] | 30 [21–40] | 25·5 [21–43] | 0.61 |
PaCO2 (kPa) | 4.98 [4.53–5.52] | 5.31 [4.56–5.6] | 5.06 [4.54–5.6] | 0.66 |
PaO2 (kPa) | 10.95 [9.43–12.45] | 11.8 [9.63–12.3] | 11.55 [9.50–12.35] | 0.54 |
SatO2 (%) | 96.6 [95.0–98.6] | 97 [93.3–98.5] | 97 [94.6–98.2] | 0.84 |
pH | 7.43 [7.39–7.46] | 7.43 [7.4–7.45] | 7.43 [7.4–7.46] | 0.74 |
HCO3-(mmol/L) | 25·1 [22.92–26.92] | 25 [23.35–27.4] | 25.1 [23–27] | 0.75 |
No immunotherapy | 5 (20) | 2 (8) | 7 (14) | 0.38 |
IvIg | 11 (44) | 17 (68) | 28 (56) | |
Plasma exchange | 6 (24) | 4 (16) | 10 (20) | |
IvIg and plasma exchange | 3 (12) | 2 (8) | 5 (10) | |